The Latest From CureMatch
In this dynamic interview, Chief Medical Advisor, Dr. Kurzrock, sits down with Michelle Morand, Co-Founder & Client Care Coordinator of Cancer Treatment Options and Management Inc. (CTOAM) to explore these topics important to cancer patients: Why genetic testing is so critical to successful treatment Why you need a personalized approach for your cancer care Why your […]
The Research Consortium announced the release of a new study today that challenges common misconceptions about combination cancer therapies, their cost, and their value. It provides payers, physicians and patients with insight as to how they can avoid wasteful spending on high-cost, low-clinical-value cancer drugs. The concurrent (on- and off-label) use of multiple FDA-approved drugs […]
CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine support for oncology, announced today that David Szekeres has been named board director. Mr. Szekeres is a seasoned executive with over 20 years in the life sciences industry, with deep operational, commercial, corporate development, strategy, financial, investor relations, and legal […]
CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine support for oncology, announced today that Dale Brown has been named board director. Mr. Brown is a growth-oriented leader with expertise across healthcare technology, pharmacy benefits, government programs, and consumer services. The founder and CEO of FrictionlessMED, a consultancy that […]
In response to President Biden’s relaunch of Cancer Moonshot and his White House commitment to end cancer as we know it, healthcare technology executives for CureMetrix and CureMatch highlighted joint innovation as core to better detection and more personalized cancer treatment. Chief medical advisor and board member, Dr. Razelle Kurzrock, visited with now President Joe […]